Health Canada open data (page 12)
Health Canada publishes 2,987 open datasets on CanQuery: 58 with live tables. Preview tables, export CSV and follow original downloads.
- Datasets
- 2987
- Queryable datasets
- 58
- Mappable datasets
- 0
Datasets
- Notice: Therapeutic Products with Paediatric Labelling
- Official Method: Conjugated Estrogens
- Official Method: Determination of Flame Projection
- Official Method: Determination of Net Contents
- Official Method: Determination of the Disintegration Time of Tablets
- Official Method: Thyroid
- Opioid Medicines – Part A: Opioid Warning Sticker
- Opioid Medicines – Part B: Opioid Patient Information Handout
- Opioid Pain Medications
- Opioid Warning Sticker and Patient Information Handout, and Risk Management Plans
- Opioid Pain Medications Frequently Asked Questions
- Pause-the-Clock Proposal for Drug and Medical Device Establishment Licence Applications
- Performance Standards for the Fees in Respect of Drugs and Medical Devices Order
- Post-Drug Identification Number (DIN) Changes Guidance Document
- Protecting Canadians from Excessive Drug Prices: Consulting on Proposed Amendments to the Patented Medicines Regulations
- Questions and Answers - Access to Drugs in Exceptional Circumstances
- Questions and Answers - Guidance Document Non-Clinical Laboratory Study Data Supporting Drug Product Applications and Submissions: Adherence to Good Laboratory Practice
- Questions and Answers Document - Structure and Content of Clinical Study Reports - ICH Topic E3(R1)
- Questions and Answers Document: Ethnic Factors in the Acceptability of foreign Clinical Data - ICH Topic E5(R1)
- Questions and Answers Regarding the Adoption of Periodic Benefit Risk Evaluation Report (PBRER) Review at Health Canada
- Questions and Answers: Prescription Opioids – Sticker and Handout Requirements for Pharmacists and Practitioners
- Registration and Disclosure of Clinical Trial Information
- Regulatory Decision Summaries
- Regulatory enrolment process (REP)
- Risk of thermal harm from therapeutic and cosmetic energy-based medical devices: Notice to industry
- Special Access Program for drugs: Guidance document for industry and practitioners
- Special Access Programme - Drugs
- Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances - ICH Topic Q6A
- Statistical Principles for Clinical Trials ICH Topic E9: Guidance for industry
- Structure and Content of Clinical Study Reports ICH Topic E3: Guidance for industry
- Guidance Document: Preparation of Premarket Medical Device Licence and Licence Amendment Applications for Dermal Fillers
- Notice: Medical Device Cybersecurity
- Notice: Phase III of Pre-Market Transparency Initiatives for Prescription Drugs
- Notice: Proposed Modification to Bioequivalence Standards for Multiphasic Modified-Release Drug Products
- Notice: Publication of the Guidance Document - Guidance for the Risk-based Classification System for In Vitro Diagnostic Devices (IVDDs)
- Clinical Development of Steroidal Contraceptives Used by Women
- Guidelines for the Toxicological Evaluation of Contraceptive Steroids
- Safety Pharmacology Studies for Human Pharmaceuticals ICH Topic S7A
- Basic Product Monograph Information for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Canada’s regulatory approach to drugs for rare diseases: orphan drugs
- Canada’s regulatory approach to drugs for rare diseases: apply and register for clinical trials
- Canada’s regulatory approach to drugs for rare diseases: find clinical trials
- Canada’s regulatory approach to drugs for rare diseases: find drug reviews and decisions
- Canada’s regulatory approach to drugs for rare diseases: our role in bringing drugs to patients
- Clinical trials and special access programs
- Clinical Trials: Registration and Disclosure of Information
- Drug and medical device approval overview
- Drug/Medical Device Combination Products
- Final Guidance Document Data Requirements for Safety and Effectiveness of Steroid Nasal Products for Use in the Treatment of Allergic Rhinitis for Industry
- Final Notice: Classification of Dental Plaque-Disclosing Products as Drugs